Understanding Overkill Sterilization: An End to the Confusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding Overkill Sterilization: An End to the Confusion
The author clarifies the definition and objectives of overkill sterilization for steam sterilization cycles. Current sterilization practices are reviewed and the validation difficulties associated with the various definitions of overkill sterilization are explored.


Pharmaceutical Technology


Sterilization processes are designed using one of three basic approaches (including the overkill method), each of which requires some degree of knowledge of the resistance and population of the bioindicator and bioburden (1). The bioburden method requires detailed knowledge and control over the bioburden resistance and population. The bioburden/biological indicator (BB/BI) method relies on the difference in resistance of the bioburden and BI (see Figure 2). With information about and control over the bioburden population and resistance, sterilization cycles requiring less time and temperature (relative to the overkill method) can be used successfully. Both of these methods allow for lower heat input to the materials being processed (an important consideration for terminal sterilization of filled product containers or the sterilization of in-process fluids and laboratory media), provided that increased attention is paid to presterilization bioburden.

The overkill method relies upon the selection of a lethality level known to be adequate to ensure sterilization without routine control over bioburden. A delivered F 0 of 12 min is an example of an overkill level of lethality. The basis for this level is that if the bioburden on an article were one million and all of that bioburden consisted of resistant spores with a D 121 value of 1 min, then a 10–6 probability of a nonsterile unit (PNSU) would be consistently attained. Obviously, this reflects worst-case assumptions regarding both the bioburden level and resistance, which would in every instance be lower in the real-world condition. The role of the BI would be to prove that there is a strong correlation between a physically determined F 0 of 12 min and biological lethality at the location of the indicator. A good correlation between biological and physical lethality ensures that an efficient and well-designed cycle with suitable steam penetration and air removal (where necessary) exists.

If understanding of overkill sterilization were all that is needed, this effort would be complete. The difficulty lies in validating overkill sterilization in a manner that is easily defendable to those unfamiliar with sterilization science and realistic in its execution. The first and simplest step is to define the minimum process objective for the sterilization process. The objective is the universal maximum probability of a single nonsterile unit (PNSU) in 106 units (a PNSU of 1 10–6 for any individual item). This is nothing more than an acceptable risk of contamination, whose origin (in the food industry) goes back many years. This criterion is the same for all sterilization processes, regardless of the sterilization method or the cycle approach used. The expectation is that the routine process will achieve the desired PNSU and that the routine process requirement does not apply to the validation effort. If that were not the case, then there would be no difference in the cycle approaches. The intent is always to establish the process such that it provides the same minimum confidence in the sterilized materials regardless of the varying controls defined.

Definitions of overkill cycles


Table I: Definitions of overkill sterilization and assessments of the validation difficulties for each.
The difficulties with overkill sterilization begin at this point. What is an overkill process? Including the currently prevalent definition of overkill given previously, there are various definitions, each of which satisfies the base requirement of a maximum PNSU of 1 in 10–6 but with varying process requirements. These definitions are presented in Table I, including assessments of the validation difficulties associated with each. It should be immediately evident, that the definitions are nonidentical, and thus the process required to achieve overkill is not constant for the various methods. The differences and difficulties associated with the varying definitions is a problem of some magnitude and is the main reason this article was developed.

What should be immediately evident is that the various definitions of overkill, and thus the validation of overkill sterilization for moist-heat processes, lack consistency. Simply put, demonstration of overkill is variable depending upon the regulatory or compendial expectations. Perhaps most unfortunate of all, none of the definitions include a requirement for nor provide a means to directly support a PNSU of 1 in 10–6, which is something every sterilization process is expected to achieve.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here